Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.
Assistant Professor Mo Maniruzzaman’s Pharmaceutical Engineering and 3D Printing (PharmE3D) labs have entered an agreement with UK-based CoM3D to develop digital 3D drug manufacturing and advanced drug delivery systems.
To meet the need to develop methods to make drugs more soluble and usable, the Maniruzzaman Lab teamed up with Advanced Material Development (AMD) to address challenges with the reduction in quantity of new drugs coming to market.
Mo Maniruzzaman‘s Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab is 3D-printing face shields to meet PPE demands at UT health institutions during the COVID-19 pandemic.
Professor Rueben Gonzales of the Department of Pharmacology and Toxicology was named a fellow of the American Association for the Advancement of Science (AAAS) for distinguished contributions to the field of alcohol research.